Cargando…
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable clinical severity and ability to escape preexisting immunity emphasizes the continued need for antiviral interventions. Two small molecule inhibitors, molnupiravir (MK-4482), a nucleoside analog, and nirmatrelvir (PF-...
Autores principales: | Rosenke, Kyle, Lewis, Matt C., Feldmann, Friederike, Bohrnsen, Eric, Schwarz, Benjamin, Okumura, Atsushi, Bohler, W. Forrest, Callison, Julie, Shaia, Carl, Bosio, Catharine M., Lovaglio, Jamie, Saturday, Greg, Jarvis, Michael A., Feldmann, Heinz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977490/ https://www.ncbi.nlm.nih.gov/pubmed/36574296 http://dx.doi.org/10.1172/jci.insight.166485 |
Ejemplares similares
-
Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques
por: Rosenke, Kyle, et al.
Publicado: (2022) -
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022) -
Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model
por: Rosenke, Kyle, et al.
Publicado: (2022) -
Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2
por: Rosenke, Kyle, et al.
Publicado: (2020) -
Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models
por: Rosenke, Kyle, et al.
Publicado: (2020)